Health Catalyst Inc. Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Sep-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Health Catalyst's ownership has been fully dispersed since its 2019 initial public offering, and 2026 marked the point at which that public-company governance structure was tested most directly, with founding CEO Dan Burton's retirement after eighteen years ending the company's last direct link to its original 2008 founding team in an executive leadership role. We think the swift sequence of events, Burton's June 2026 retirement, an interim period under Ben Albert, and the September 2026 appointment of outside executive Simeon Kohl, formerly CEO of Performant Healthcare, demonstrates that Health Catalyst's board treated the leadership transition as a genuine opportunity to bring fresh, externally sourced perspective rather than simply promoting from within to preserve founding-era continuity. In our assessment, the 2026 divestiture of Vitalware for $147 million, sold specifically to help retire a roughly $160 million term loan, represents an unusually direct example of a widely held public company's board prioritizing balance sheet discipline over continuing to hold a strategically acquired asset, a decision that required genuine institutional distance from the original 2020 acquisition decision. We believe Health Catalyst's fiscal 2025 results, $311.1 million in revenue against a net loss of $177.97 million including a $110.2 million impairment charge, underscore why this governance reset mattered: the company needed decisive action on both leadership and balance sheet questions simultaneously, and its dispersed, independent ownership structure allowed the board to act on both fronts within the same year. For Health Catalyst shareholders, we think the central ownership-related question now is whether new CEO Simeon Kohl, arriving with no prior Health Catalyst tenure, can translate this structural reset into a genuinely improved path to profitability.
Direct Owners
Institutional Shareholders
Shareholder Analysis
First Light Asset Management holds the largest identifiable position in Health Catalyst at roughly 17%, a notably concentrated stake for a widely held public company where institutional investors collectively own roughly 85% of shares outstanding. We think the absence of Health Catalyst's original venture capital backers, firms like Sequoia Capital and Kaiser Permanente Ventures that funded the company's pre-IPO growth, from today's largest shareholder list reflects a fairly typical pattern for a company now seven years removed from its 2019 initial public offering, as early venture investors gradually rotate out of public positions over time. In our reading, Health Catalyst's roughly 1,200 employees generated $311.1 million in fiscal 2025 revenue but posted a net loss of $177.97 million, a result heavily affected by a $110.2 million impairment charge that likely reflects the board's reassessment of certain acquired assets' carrying value, quite possibly foreshadowing the Vitalware divestiture that followed in 2026. We calculate that this combination, a concentrated but not controlling top shareholder, substantial institutional ownership overall, and a board willing to take material impairment charges and pursue asset divestitures, suggests a shareholder base genuinely engaged with pushing for balance sheet discipline rather than passively tolerating continued losses. For Health Catalyst shareholders, we believe the practical significance of this ownership structure is that it provided the governance latitude for the board to execute a genuinely difficult sequence of decisions in 2026, a CEO transition, an interim leadership period, a new outside CEO hire, and a material divestiture, all within a matter of months.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| Health Catalyst Data Operating System | Platform | Core healthcare data and analytics technology platform underlying the company's products |
| Twistle by Health Catalyst | Subsidiary | Patient engagement and automated care journey technology, acquired in 2021 |
| Carevive Systems | Subsidiary | Oncology and cancer care planning technology, acquired in 2023 |
| Able Health | Subsidiary | Quality measure reporting and value-based care technology, acquired in 2019 |
| Medicity | Subsidiary | Health information exchange and clinical data interoperability technology, acquired in 2018 |
Portfolio Analysis
Health Catalyst's brand strategy centers on its core Data Operating System platform, with acquired capabilities like Twistle and Carevive Systems retaining recognizable sub-brand identities, Twistle by Health Catalyst, Carevive Systems, rather than being fully absorbed into an undifferentiated parent product line. We think this approach reflects the genuinely technical, specialized nature of Health Catalyst's healthcare provider and life sciences customer base, where a hospital system evaluating oncology care planning technology likely responds better to Carevive's established clinical credibility than to a generic Health Catalyst-branded alternative built from scratch. In our assessment, the 2026 divestiture of Vitalware represents a meaningful brand portfolio contraction, removing revenue integrity and coding technology from Health Catalyst's offering entirely rather than continuing to market it alongside the company's core data and analytics platform, a signal that management concluded Vitalware no longer fit the company's focused strategic direction as cleanly as it once appeared to. We believe the remaining brand portfolio, Medicity's interoperability technology, Able Health's quality measure reporting, Twistle's patient engagement tools, and Carevive's oncology planning capability, still represents a genuinely broad set of specialized healthcare technology capabilities organized under the Data Operating System umbrella, even after the Vitalware exit narrowed the overall footprint. For Health Catalyst shareholders, we think new CEO Simeon Kohl's early strategic priorities will likely include clarifying whether further brand portfolio simplification should follow the Vitalware divestiture, or whether the remaining acquired capabilities represent a coherent, complementary set worth continuing to market together under the core Health Catalyst identity.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Definitive Healthcare | N/A | N/A FY2025 | Healthcare commercial intelligence and data analytics company competing for similar provider and life sciences clients |
| Certara | N/A | N/A FY2025 | Biosimulation and regulatory science software company serving adjacent healthcare data and analytics markets |
| Premier Inc. | N/A | N/A FY2025 | Healthcare performance improvement and supply chain data company competing for hospital system technology budgets |
| Health Catalyst ★ | N/A | $311.1M FY2025 | Healthcare data and analytics technology company built on its Data Operating System platform |
Competitive Analysis
Health Catalyst's $311.1 million in fiscal 2025 revenue positions it as a genuine mid-sized specialist within the broader healthcare data and analytics technology market, competing against Definitive Healthcare's commercial intelligence platform, Certara's biosimulation and regulatory science software, and Premier Inc.'s performance improvement and supply chain data offerings, each targeting overlapping but distinctly different segments of hospital and life sciences technology budgets. We think Health Catalyst's core competitive differentiation lies in its Data Operating System platform's breadth, spanning interoperability, quality reporting, patient engagement, and oncology care planning through its various acquired capabilities, a more comprehensive provider-focused offering than narrower point-solution competitors typically provide. In our assessment, the company's fiscal 2025 net loss of $177.97 million, including a substantial impairment charge, suggests Health Catalyst has faced real competitive and margin pressure translating platform breadth into sustainable profitability, a challenge new CEO Simeon Kohl inherits directly from his September 2026 appointment. We believe the 2026 Vitalware divestiture, removing revenue integrity and coding technology from the portfolio, may represent a strategic narrowing specifically aimed at competing more effectively in Health Catalyst's core data and analytics strength areas rather than continuing to stretch resources across an increasingly broad, difficult-to-differentiate product set. For Health Catalyst shareholders, we think the central competitive question under new leadership is whether a more focused platform, following the Vitalware exit, can achieve the operating leverage and profitability that competitors like Certara and Definitive Healthcare have arguably demonstrated more consistently in recent years.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| Medicity | N/A | 2018 | Acquired the health information exchange and clinical data interoperability business on undisclosed terms |
| Able Health | N/A | 2019 | Acquired the quality measure reporting and value-based care technology company on undisclosed terms |
| Vitalware | $120.0M | 2020 | Acquired the healthcare revenue integrity and coding technology company; divested in 2026 for $147 million to help retire a term loan |
| Twistle | N/A | 2021 | Acquired the patient engagement and automated care journey technology company on undisclosed terms |
| Carevive Systems | N/A | 2023 | Acquired the oncology and cancer care planning technology company on undisclosed terms |
Acquisitions Analysis
Health Catalyst spent roughly a decade and a half accumulating specialized healthcare technology capability through acquisition, Medicity in 2018, Able Health in 2019, Vitalware for $120 million in 2020, Twistle in 2021, and Carevive Systems in 2023, before reversing course in 2026 with the $147 million divestiture of Vitalware. We think this reversal deserves close attention specifically because Vitalware was sold for more than its original $120 million purchase price, suggesting the divestiture reflected genuine balance sheet necessity, helping retire a roughly $160 million term loan, rather than a distressed sale of an underperforming asset at a loss. In our assessment, the broader pattern across Health Catalyst's acquisition history, adding interoperability, quality reporting, revenue integrity, patient engagement, and oncology planning capabilities in roughly that sequence, reflects an ambitious attempt to build a comprehensive healthcare data and analytics platform spanning the full continuum of provider technology needs, an ambition the 2026 Vitalware exit suggests management has now decided to narrow somewhat. We note that Health Catalyst's fiscal 2025 net loss of $177.97 million, including a $110.2 million impairment charge, likely provided the financial pressure that made continued ownership of every previously acquired asset increasingly difficult to justify, setting the stage for the Vitalware sale that followed. For Health Catalyst shareholders, we believe the practical lesson from this acquisition-then-divestiture arc is that even a genuinely strategic, well-reasoned string of technology acquisitions can eventually require selective pruning when balance sheet pressure mounts, a discipline new CEO Simeon Kohl will need to continue applying carefully to the company's remaining portfolio.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Health Catalyst's structural history divides cleanly into two phases: nearly a decade and a half of steady acquisition-driven platform building from 2018 through 2023, followed by an abrupt reversal in 2026 that combined a major divestiture with a complete leadership change. We think the timing of these 2026 events, Dan Burton's June retirement after eighteen years as founding CEO, the Vitalware divestiture, and Simeon Kohl's September appointment as the new outside CEO, together represent the most significant structural inflection point in Health Catalyst's history as a public company, a genuinely comprehensive reset touching leadership, portfolio composition, and balance sheet simultaneously. The $147 million Vitalware sale, exceeding the business's original $120 million purchase price from 2020, suggests this wasn't a fire sale forced by desperate circumstances but rather a considered decision to monetize a valuable but no longer strategically essential asset specifically to address a roughly $160 million term loan obligation. We note that Health Catalyst's earlier acquisition sequence, Medicity, Able Health, Twistle, and Carevive Systems, none individually disclosed with a dollar value, reflects a company that built scale through numerous smaller technology tuck-ins rather than one or two transformative deals, a pattern that made 2026's single, large, clearly quantified divestiture all the more structurally distinctive by comparison. For Health Catalyst shareholders, we believe this history demonstrates that even a company built primarily through accumulation can execute a genuine strategic reversal when balance sheet and leadership circumstances demand it, provided the board has the independence to act decisively.
Ownership History
Ownership History Analysis
Dan Burton, Tom Burton, and Steve Barlow founded Health Catalyst in 2008, building the company with venture backing from investors including Sequoia Capital and Kaiser Permanente Ventures before its 2019 initial public offering on the Nasdaq established today's widely held public ownership structure. We think Dan Burton's eighteen-year tenure as Chief Executive Officer, spanning the company's entire journey from startup through IPO and a lengthy string of acquisitions, represented an unusually long run of founder-led continuity for a publicly traded healthcare technology company, making his June 2026 retirement a genuinely significant milestone rather than a routine leadership change. The subsequent interim period under Ben Albert, followed by the September 2026 appointment of Simeon Kohl, previously CEO of Performant Healthcare, marks the first time in Health Catalyst's eighteen-year history that leadership has passed to an executive with no prior connection to the company's founding team. We believe the concurrent 2026 divestiture of Vitalware, sold for $147 million against fiscal 2025 results showing a $177.97 million net loss including a $110.2 million impairment charge, suggests the new leadership era began amid genuine financial pressure requiring immediate strategic action rather than a smooth, low-stakes handoff. For Health Catalyst shareholders, the arc from a 2008 startup through eighteen years of Dan Burton's leadership to today's post-transition company under Simeon Kohl illustrates both the durability and the eventual limits of founder-led leadership, even at a company that never had a controlling founder ownership stake to begin with.
Ownership Explained
Health Catalyst has been a widely held public company with no controlling shareholder since its 2019 initial public offering on the Nasdaq, a genuine transition from its earlier venture-backed history when investors including Sequoia Capital and Kaiser Permanente Ventures funded the company's growth. Institutional investors now hold roughly 85% of shares outstanding, with First Light Asset Management the largest disclosed holder at roughly 17%, while the original venture backers no longer appear among the company's largest shareholders following years of public market trading and share turnover. The company underwent significant leadership change in 2026: founding CEO Dan Burton, who had led Health Catalyst for eighteen years since its 2008 founding, retired in June 2026, with Ben Albert serving as interim Chief Executive Officer before Simeon Kohl, previously CEO of Performant Healthcare, was appointed CEO effective September 14, 2026. That leadership transition coincided with the divestiture of Vitalware, a revenue integrity technology business the company had acquired in 2020, sold in 2026 for $147 million to help retire outstanding debt.
As a fully independent, widely held public company with no controlling shareholder, Health Catalyst's strategic direction now rests with an independent board and professional management rather than with any founding venture investor or family interest, a genuine transition that became fully evident with founder Dan Burton's 2026 retirement after eighteen years at the helm. That governance structure enabled the board to pursue the Vitalware divestiture as a deliberate balance sheet management decision, prioritizing debt reduction over continuing to hold a previously acquired business, a strategic reversal that a founder more emotionally attached to the company's acquisition history might have resisted. For shareholders, the practical implication of 2026's dual leadership transition and Vitalware sale is that Health Catalyst's next chapter under new CEO Simeon Kohl will be judged on genuinely fresh strategic merits, unconnected to the founding team's original vision, a meaningful inflection point for a company now eighteen years removed from its 2008 founding.